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Abstract
Subunit vaccines are significantly more expensive to produce than traditional vaccines because they are based primarily on
recombinant proteins that must be purified from the expression system. Despite the increased cost, subunit vaccines are
being developed because they are safe, effective, and can elicit antibodies that confer protection against diseases that are
not currently vaccine-preventable. Algae are an attractive platform for producing subunit vaccines because they are
relatively inexpensive to grow, genetically tractable, easily scaled to large volumes, have a short generation time, and are
devoid of inflammatory, viral, or prion contaminants often present in other systems. We tested whether algal chloroplasts
can produce malaria transmission blocking vaccine candidates, Plasmodium falciparum surface protein 25 (Pfs25) and 28
(Pfs28). Antibodies that recognize Pfs25 and Pfs28 disrupt the sexual development of parasites within the mosquito midgut,
thus preventing transmission of malaria from one human host to the next. These proteins have been difficult to produce in
traditional recombinant systems because they contain tandem repeats of structurally complex epidermal growth factor-like
domains, which cannot be produced in bacterial systems, and because they are not glycosylated, so they must be modified
for production in eukaryotic systems. Production in algal chloroplasts avoids these issues because chloroplasts can fold
complex eukaryotic proteins and do not glycosylate proteins. Here we demonstrate that algae are the first recombinant
system to successfully produce an unmodified and aglycosylated version of Pfs25 or Pfs28. These antigens are structurally
similar to the native proteins and antibodies raised to these recombinant proteins recognize Pfs25 and Pfs28 from P.
falciparum. Furthermore, antibodies to algae-produced Pfs25 bind the surface of in-vitro cultured P. falciparum sexual stage
parasites and exhibit transmission blocking activity. Thus, algae are promising organisms for producing cysteine-disulfide-
containing malaria transmission blocking vaccine candidate proteins.
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Introduction
Vaccines have transformed medicine and dramatically im-
proved human health. However, traditional vaccines that consist
of attenuated or killed pathogens are not always practical or
effective. A more modern strategy is to present specific immuno-
genic subunits from a pathogen to the immune system [1,2].
Antibodies raised to these subunit vaccines, which are generally
recombinant proteins or synthesized peptides, recognize native
proteins from the appropriate pathogen and confer protection to
the vaccinated individual. This reductionist approach is generally
safer than traditional vaccines because there is no risk of a
recombinant protein becoming virulent, and protein subunits
promote a more directed immune response because of decreased
antigenic competition. In the United States, vaccines cost $10–120
per dose (Center for Disease Control; [3]) with subunit vaccines
being the most expensive. Though impoverished nations would
benefit the most from potential subunit vaccines for malaria,
dengue, and other diseases for which traditional vaccines do not
exist, the cost of recombinant subunit vaccines is too expensive for
use in these areas [4]. Thus, cheaper methods for producing
subunit vaccines should be a priority if we are to reduce the heavy
disease burdens found in low income countries.
Every system used to produce recombinant proteins has its own
advantages and disadvantages with respect to cost, protein folding,
yield, ease of manipulation, and scalability, which must be
carefully weighed against the specific application and structure
of the antigen. One strategy for reducing the cost of subunit
vaccines is to use plants as the expression system [5,6].
Photosynthetic growth, combined with high recombinant protein
yields and economy of scale, result in a relatively inexpensive
production platform [7]. In plants, both the nuclear and plastid
genome can be transformed with genes that encode subunit
vaccines. Indeed, several plant-made pharmaceuticals are cur-
rently in clinical trials [8]. Microalgae, which are essentially single-
celled water-borne plants, are easily manipulated, have much
shorter generation times than terrestrial plants, and can be
cultured in complete containment at a relatively low cost. The
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co-products that could be produced concurrently, thus driving
down the cost of both the fuel and any associated algae-produced
protein. The chloroplast of the eukaryotic green microalgae,
Chlamydomonas reinhardtii, is genetically tractable and has been used
to produce human monoclonal antibodies [9,10], human protein
therapeutics [11], and subunit vaccines [12,13]. However, the
diversity of recombinant proteins that can be produced in algal
chloroplasts is still not well-explored. We tested whether algal
chloroplasts can produce malaria transmission blocking vaccines
(TBV) by producing the well-studied structurally complex malaria
TBV candidates, Plasmodium falciparum surface protein 25 (Pfs25)
and 28 (Pfs28).
The Plasmodium parasite that is the causative agent of malaria
can only be transmitted via the female Anopheles mosquito. There it
undergoes the sexual stages of development that eventually lead to
the infectious sporozoites that reside in the mosquito salivary gland
[14]. Several conserved proteins involved in this process, in
particular Pfs25, are of great interest because antibodies raised to
these proteins block parasite maturation leading to sporozoites,
thus preventing subsequent transmission to a human host [15]. A
TBV would complement current vector control strategies and
increase the efficacy of the protective RTS/S vaccine [16,17], but
a safe and effective TBV has not been realized despite its initial
conception in 1976 [18,19].
Pfs25 and Pfs28 are structurally complex aglycosylated outer
membrane proteins that contain four tandem epidermal growth
factor-like (EGF) domains, each with several disulfide bonds. The
biological limitations of traditional recombinant systems have
made it difficult to reproduce the complex structures of these
proteins. Attempts to produce conformationally correct Pfs25 in
Escherichia coli failed [20], and yeast-produced Pfs25 has multiple
conformations [21,22] and caused an allergic reaction during
human clinical trials [23]. More recently, Pfs25 was produced in a
tobacco transient expression system and is a promising TBV
candidate [24], but like yeast, requires mutations in the nucleotide
sequence to prevent post-translational glycosylation. Furthermore,
transient expression mediated by Agrobacterium infiltration may not
be as suitable for large scale production as algae. Like yeast and
tobacco, the chloroplast of green algae can fold complex proteins
and make disulfide bonds, but lacks the machinery for glycosyl-
ation. Here we describe the physical and immunological
characteristics of algae-produced Pfs25 and Pfs28.
Results
Production and purification of recombinant Pfs25 and
Pfs28 in algal chloroplasts
We synthesized genes encoding pfs25(Ala22 – Thr193) and
pfs28(Val24 – Pro179) with a codon bias that resembles the C.
reinhardtii chloroplast codon usage (hereafter referred to as a-pfs25
and a-pfs28). Codon optimization of heterologous genes for
expression in the chloroplast was previously shown to increase
protein yields [25]. Synthetic a-pfs25 and a-pfs28 each contain four
EGF-like domains and a C-terminal FLAG tag for ease of
detection and purification, but lack the native signal sequence and
GPI-anchor sequence. The expected codon adaptation index
(eCAI), which quantitates the codon bias of a transgene against a
reference set, is 0.878 (p,.01) and 0.892 (p,. 01) for a-pfs25 and
a-pfs25 respectively [26]. CAI values range from zero to one where
a score of one indicates that every instance of an amino acid is
encoded by the most common codon in the reference codon table
[27]. A-pfs25 and a-pfs28 were synthesized and separately cloned
into a chloroplast expression cassette that replaces endogenous
psbA through homologous recombination such that transgene
expression is controlled by the psbA promoter and 59 and 39
untranslated regions (UTRs; Fig. 1A). C. reinhardtii chloroplasts
were transformed by particle bombardment and a-pfs25 and a-
pfs28 were detected by PCR (data not shown). Transformed C.
reinhardtii were screened for a-Pfs25 (Fig. 1B – arrow) and a-Pfs28
(Fig. 1C – arrow) protein by Western blot. A-Pfs25 and a-Pfs28
accumulate in chloroplasts at 0.5% and 0.2% total soluble protein,
respectively, as determined by ELISA (see materials and methods).
A-Pfs25 and a-Pfs28 were affinity purified using anti-FLAG M2
affinity resin (see materials and methods), positively identified by
mass spectrometry (data not shown), and analyzed by Western blot
(Fig. 2A–B). The predominant band in reduced a-Pfs25 and a-
Pfs28 migrated near their predicted sizes of 21.4 kDa (Fig. 2A –
arrow) and 20.2 kDa (Fig. 2B – arrow), respectively. The sizes of
the larger bands suggest that a-Pfs25 and a-Pfs28 could be running
as dimers. The monomeric form of a-Pfs25 and a-Pfs28 is
diminished in unreduced samples and appears at larger, less well-
defined molecular species. Similar to Western blot analysis,
Coomassie-blue staining of reduced samples resolved by SDS-
PAGE shows a single predominant band with few obvious
impurities for both a-Pfs25 and a-Pfs28 (Fig. 2C). Similar results
were obtained with silver staining (Fig. S1). A-Pfs25 and a-Pfs28
appear as larger less defined molecular weight complexes when
analyzed by native-PAGE (Fig. 2D). The apparent larger size of a-
Pfs25 and a-Pfs28 in the non-reduced and native gels could be the
result of multimerization that form because both proteins are rich
in b-strand secondary structures that are known to interact [28].
Indeed, multimerization of recombinant Plasmodium surface
proteins was recently observed [29,30]. Thus, algal chloroplasts
produce a single protein that is the appropriate size for a-Pfs25 and
a-Pfs28, and those monomers appear to assemble into higher
molecular weight aggregates that could have multiple conforma-
tions.
Structural characterization of a-Pfs25 and a-Pfs28
A-Pfs25 and a-Pfs28 were analyzed for the presence of epitopes
found in native Pfs25 and Pfs28 by Western blot using
transmission blocking monoclonal antibodies 4B7 (Pfs25, [31])
and 2D8 (Pfs28, a gift from David Narum, NIAID [32]), which
were previously shown to recognize epitopes only present on
properly folded Pfs25 and Pfs28, respectively(Fig. 3). Anti-Pfs25-
4B7 mAbs recognize a b-hairpin epitope within the
ILDTSNPVKT peptide sequence of the third EGF-like domain
of native Pfs25 [33,34]. Anti-Pfs25-4B7 mAbs binds a-Pfs25 as a
band that migrates between 100 and 130 KDa in non-reduced
samples (Fig. 3A). Unlike anti-FLAG mAbs (Fig. 2), anti-Pfs25-4B7
does not recognize reduced a-Pfs25, which is consistent with
recognition being conformationally dependent. Similarly, anti-
Pfs28-2D8 mAbs recognize a-Pfs28 in non-reduced, but not
reduced samples, as a larger molecular weight species (Fig. 3B).
Thus, a-Pfs25 and a-Pfs28 contain epitopes present on native
Pfs25 and Pfs28, respectively.
We assessed the secondary structure of purified a-Pfs25 and a-
Pfs28 using circular dichroism (CD) spectroscopy(Fig. 4A). The
crystal structure of yeast-produced Plasmodium vivax surface protein
25 (Pvs25), a homologue of Pfs25, has two central b-strands
separated by a turn [35]. Bioinformatic analysis of Pfs25 and Pfs28
suggest their structures are similar [33]. Deconvolution of CD
spectra with CDSSTR [36,37], which estimates the contribution
of each secondary structure to the overall spectrum, predicts that
a-Pfs25 and a-Pfs28 are composed of nearly 60% b-strands and
turns, 10% a-helix, and 30% unordered peptide. Thus, the CD
spectra reveal that a-Pfs25 and a-Pfs28 have comparable
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37179secondary structures that are predicted to be primarily b-strands
and turns, which is consistent with the crystal structure of Pvs25.
We analyzed free cysteine residues in a-Pfs25 by mass
spectrometry to determine which residues are bridged by disulfide
bonds (see materials and methods). Briefly, a-Pfs25 was treated
with iodoacetamide to carboxymethylate free cysteines followed by
trypsin digestion. Tryptic peptides were analyzed by high pressure
liquid chromatography (HPLC) coupled to tandem mass spec-
trometry (LC-MS-MS) using nanospray ionization. Presumably,
cysteines that remained unmodified after treatment with iodoace-
tamide were protected from modification because they were in
disulfide bonds. The detected peptides covered approximately
64% of the Pfs25 sequence (Fig. 4B – underlined). A-Pfs25
digested with GluC and chymotrypsin did not add to the total
coverage (data not shown). When compared to the disulfide bonds
identified in crystallized yeast-produced Pvs25, we found that
disulfide bonds 1, 4, and 6 are intact while 2, 7, 8, 10, and 11 may
not be completely formed in a-Pfs25. Peptides for the remaining
disulfide bonds were not detected. Hence, C. reinhardtii chloroplasts
Figure 1. Diagram of chloroplast transformation vector and Western blots of C. reinhardti transformed with vectors containing
codon optimized pfs25 or pfs28. (A) The codon optimized nucleotide sequences corresponding to EGF domains 1–4 of pfs25 and pfs28 were
separately cloned into an open reading frame that is upstream of a TEV protease site and FLAG epitope. Transgenes were integrated at the psbA locus
by homologous recombination. Gene expression is driven by the psbA promoter and mRNA is stabilized by the psbA 59 and 39 untranslated regions
(UTRs). (B) Western blot analysis of purified algae-produced HMGB1 containing a FLAG epitope (lane 1), lysate of untransformed parental strain (lane
2), lysate of C. reinhardtii containing a-pfs25 total protein (lane 3) and soluble protein (lane 4) probed with anti-FLAG mAbs. (C) Western blot using
anti-FLAG mAbs of purified algae-produced HMGB1 containing a FLAG epitope (lane 1), lysate of untransformed parental strain (lane 2), lysate of C.
reinhardtii containing a-pfs28 total protein (lane 3) and soluble protein (lane 4) probed with anti-FLAG mAbs.
doi:10.1371/journal.pone.0037179.g001
Figure 2. Immunoblot and Coomassie-blue stain of algae-produced Pfs25 and Pfs28 analyzed by SDS and Native-PAGE. Five
micrograms of reduced and non-reduced affinity purified (A) a-Pfs25 and (B) a-Pfs28 were resolved by SDS-PAGE, transferred to nitrocellulose, and
detected with anti-FLAG mAbs. (C) Five micrograms of reduced a-Pfs25, a-Pfs28, and BSA were resolved by SDS-PAGE and stained with Coomassie-
blue. (D) Five micrograms of non-reduced a-Pfs25, a-Pfs28, and BSA were resolved by Native-PAGE and stained with Coomassie-blue. (R – reduced, N
– non-reduced).
doi:10.1371/journal.pone.0037179.g002
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bridged by disulfide bonds as yeast-produced Pfs25.
Antibodies from mice vaccinated with a-Pfs25 or a-Pfs28
recognize native parasite proteins
Balb/c mice were immunized with affinity purified a-Pfs25 or a-
Pfs28 using complete Freund’s adjuvant for the first vaccination
and incomplete Freund’s adjuvant for subsequent vaccinations (see
materials and methods). Antibody titers were measured by ELISA
against affinity purified a-Pfs25 or a-Pfs28 (Fig. 5A). Sera from
mice immunized with a-Pfs25 and a-Pfs28 contained high titers of
antibodies for a-Pfs25 and a-Pfs28 respectively. Pre-immune sera
showed no IgG response to either of these proteins.
We tested the specificity of antibodies raised to algae produced
Pfs antigens to native Pfs25 or Pfs28 in sexual stage parasite
lysates. Reduced and non-reduced P. falciparum sexual stage lysates
were probed with anti-Pfs25-4B7 mAbs, anti-Pfs28-2D8 mAbs,
and with serum from mice injected with a-Pfs25 or a-Pfs28. As
expected, anti-Pfs25-4B7 recognized a band in the non-reduced
sample, but not the reduced sample, which is consistent with anti-
Pfs25-4B7 recognizing only conformationally-correct Pfs25
(Fig. 4B). Sera from mice injected with a-Pfs25 recognized a
25 kDa band in reduced P. falciparum lysates, which is consistent
with molecular weight of native Pfs25, and an approximately
40 KDa band that is identical in size to the band recognized by
anti-Pfs25-4B7 in non-reduced lysates (Fig. 5B & C). Antibodies
raised to a-Pfs28 recognized an approximately 22 KDa band in
both reduced and non-reduced parasite lysates (Fig. 5D), but
required ten-fold more parasite lysate than a-Pfs25 antisera for
detection. This could be due to lower Pfs28 protein abundance or
due to lower affinity antibodies. We did not detect Pfs28 with anti-
Pfs28-2D8 mAbs (data not shown) indicating Pfs28 is indeed less
abundant than Pfs25 in our in vitro cultured parasites. Importantly,
the size of the protein recognized by a-Pfs28 antisera is consistent
with antibodies that were previously shown to recognize Pfs28 in
sexual stage parasites [38]. Thus, antisera to both a-Pfs25 and a-
Pfs28 recognize native parasite proteins of the appropriate size and
a-Pfs25 antisera recognize a band that identical to the transmission
blocking anti-Pfs25 4B7 mAbs in non-reduced samples.
Pfs25 and Pfs28 are outer membrane proteins that are produced
in P. falciparum sexual stage parasites [39]. We therefore tested the
affinity of a-Pfs25 and a-Pfs28 antisera as well as anti-Pfs25-4B7
mAbs and sera from unvaccinated isogenic mice for in-vitro
cultured parasites. Binding of a-Pfs25 antisera was predominantly
confined to the outer membrane(Fig. 6A; additional images Fig.
S2). Staining with anti-Pfs25-4B7 was identical to a-Pfs25 antisera
(Fig. 6B & Fig. S2), which suggests antibodies to a-Pfs25 also bind
Pfs25. Binding of a-Pfs28 antisera was significantly weaker than a-
Pfs25 antisera and often not detectable above background levels
seen with sera from unvaccinated isogenic mice (Fig. S2). Similar
to Western blot analysis of parasite lysates, this suggests that
antibody titers to Pfs28 are low or that Pfs28 is not as abundant as
Pfs25 in our in-vitro cultured parasites.
Evaluation of transmission blocking activity of a-Pfs25
and a-Pfs28 antisera
Transmission blocking activity was measured by the reduction
of oocysts in mosquito midguts by a standard membrane feed
assay (SMFA). Briefly, P. falciparum NF 54 gametocytes and heat
inactivated antisera from mice immunized with a-Pfs25, a-Pfs28,
or sera from isogenic mice were fed to female Anopheles stephensi
mosquitoes. Mosquitos were dissected nine days later and analyzed
for oocysts (Fig. 7). Oocyst counts were reduced in mosquitos that
were fed a-Pfs28 antisera, but transmission blocking activity did
not reach significance using a nonparametric comparison test (see
materials and methods). Antibodies to a-Pfs25 completely blocked
transmission as indicated by the absence of oocysts in all dissected
mosquitos. These results are consistent with previous data that
suggests that antibodies to Pfs25 more efficiently block malaria
transmission than antibodies to Pfs28 [21,40], and that the algal
expressed a-Pfs25 protein elicits an antibody response most
suitable for vaccine development.
Discussion
In this study, we demonstrated that algae are a robust platform
for producing malaria subunit vaccines by characterizing Pfs25
and Pfs28, two structurally complex malaria transmission blocking
vaccine candidates, made in C. reinhardtii chloroplasts. Algae are
the only recombinant system to date that has successfully produced
unmodified aglycosylated recombinant Pfs25 or Pfs28. The algae-
produced recombinant proteins are similar in structure to native
Pfs25 and Pfs28 and are recognized by transmission blocking
monoclonal antibodies that only bind conformationally correct Pfs
antigens. Analysis of free cysteines in a-Pfs25 revealed that
disulfide bonds are formed by algal chloroplasts in this protein,
but these may not be as extensively formed as in the yeast-
produced homologue, Pvs25 from P. vivax [35], and this may be an
area where the algae system can be improved. However, the
disulfide linkages in native Pfs25 are not known, nor have they
been characterized in any other recombinant system. The disulfide
bonds are likely similar to the native protein because both a-Pfs25
and a-Pfs28 elicit antibodies in mice that recognize native proteins
in P. falciparum sexual stage lysates. A-Pfs25, but not a-Pfs28,
elicited antibodies with significant levels of transmission blocking
activity, which is consistent with previous observations [21,40].
The structural analysis of a-Pfs25 and a-Pfs28 suggests these
antigens resemble the native proteins and are of similar
conformational quality. The apparent difference in transmission
Figure 3. Immunoblot of reduced and non-reduced algae-
produced Pfs25 and Pfs28 with monoclonal transmission
blocking antibodies. Reduced and non-reduced a-Pfs25 and a-
Pfs28 were resolved by SDS-PAGE, transferred to nitrocellulose, and
detected with (A) anti-Pfs25 4B7 mAb and (B) anti-Pfs28-2D8 mAbs,
respectively.
doi:10.1371/journal.pone.0037179.g003
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delayed appearance of Pfs28 in ookinete development compared
to the earlier appearance of Pfs25 in zygote development,
rendering any antibodies directed against the later-expressed
Pfs28 protein on the parasite superfluous. For these reasons,
interest in Pfs28 as a TBV candidate has diminished in recent
years compared to Pfs25, which remains the lead TBV candidate.
TBVs and other subunit vaccines must be produced at a cost
that is appropriate for low income countries if they are to be
implemented. Indeed, financial constraints are already limiting the
dissemination of effective meningococcal, pneumococcal, and
rotavirus vaccines [41]. Algal biomass could be a low cost source
for recombinant protein, especially because recent interest in algal
biofuels is driving research in large scale algae cultivation, which is
certain to reduce the price of algal biomass production.
Recombinant proteins could be separated from lipids used for
fuel production, which would drive down the cost of both.
Alternatively, fusing mucosal adjuvants to vaccine candidates
might allow for oral delivery and eliminate the need for injection
and cold chain storage [6,13], both of which significantly
contribute to vaccine cost. Unicellular green algae like C. reinhardtii
are generally regarded as safe by the U.S. Food and Drug
administration because they do not harbor endotoxins, human
pathogens, or other known toxic compounds. Therefore, algae
may be an ideal platform for producing low-cost subunit vaccines.
Figure 4. Structural analysis of algae-produced Pfs25 and Pfs28. (A) Far-UV circular dichroism spectra of algae-produced Pfs25 (Gray) and
Pfs28 (Black). Spectra shown are measured mean residue ellipticity (solid lines) and best fit (dotted lines) using CDSSTR. The contribution of each
secondary structure to the overall spectra as predicted by CDSSTR is shown as fractions. (B) Analysis of protected cysteines in a-Pfs25 by tandem mass
spectrometry. The peptide sequence of Pfs25 from Ala22 to Thr193 is shown with EGF-like domain 1 (blue), 2(pink), 3(green), 4(orange). Peptides
detected by mass spectrometry are underlined and protected cysteines are marked by stars. Predicted disulfide linkages between cysteines are
marked numerically (i.e. the two cysteines labeled 1 form a dilsulfide linkage and so on). The epitope recognized by anti-Pfs25 4B7 mAb is indicated.
doi:10.1371/journal.pone.0037179.g004
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Plasmid construction
The peptide sequences of Pfs25(Ala22 – Thr193) (Genbank
accession: AAD55785) and Pfs28(Val24 – Pro179) (Genbank
accession: AAG27295) were reverse translated with the gene
designer algorithm from DNA2.0 (Menlo, CA, USA) using the C.
reinhardtii complete codon usage table as a reference set (http://
www.kazusa.or.jp). The codon bias of the sequence was validated
by computing the expected codon adaptation index (eCAI) [26].
The codon optimized algal-pfs25 (a-pfs25) and algal-pfs28 (a-pfs28)
were synthesized by GeneArtH(now Life Technologies Carlsbad,
CA, USA) and cloned into the pD1-KanR [11], which contains 59
and 39 psbA homology to direct homologous recombination to the
psbA locus and a kanamycin resistance cassette for selection. The
resulting plasmids contain a-pfs25 (pJAG9) or a-pfs28 (pJAG15)
fused to a 39 TEV protease recognition sequence followed by a
FLAG affinity tag. Synthetic pfs genes are downstream of the psbA
promoter and 59 UTR and upstream of the psbA 39 UTR. Each
construct was verified by sequencing (Retrogen, San Diego, CA).
C. reinhardtii transformation
C. reinhardtii strain W1.1 [42] was grown in TAP (Tris-acetate-
phosphate) medium at 23uC on a rotary shaker to mid log phase
and harvested by centrifugation. Approximately 5610
7 cells were
plated on TAP agar with 100 ug/ml kanamycin and transformed
by particle bombardment [43]. Briefly, 1 mg of gold particles
(S550d, Seashell technologies, San Diego) coated with 10 ug of
plasmid DNA were shot with the PDS-1000/He system (Biorad,
Hercules, CA) under vaccum at a distance of 9 cm at 1350 psi.
Transformants were propagated on TAP agar with 150 ug/mL
kanamycin and screened for the presence of a-pfs25 or a-pfs28
using gene specific primers and for homoplasmicity as previously
described [44].
Western blotting, Silver Staining, and affinity purification
of a-Pfs25 and a-Pfs28
Initial screens for Pfs protein were performed on homoplasmic
strains in 250 ml TAP cultures grown on a rotary shaker. Cultures
were grown in low light to mid log phase and then switched to
high light (,5000 lux) conditions. Samples were harvested at
various timepoints post-light shift and resuspended in 1 ml lysis
buffer per 0.1 g wet algal paste (50 mM Tris pH 8.0, 400 mM
NaCl, 0.1% Tween 20, protease inhibitor cocktail (Roche –
Mannheim, Germany)). Cells were lysed by sonication and cleared
by centrifugation at 30,0006G for 15 minutes. Total and soluble
protein samples were prepared in SDS buffer with urea and DTT
at a final concentration of 50 mM Tris, 2% SDS, 10% glycerol,
2 M urea, and 100 mM DTT. Samples were heated at 37uC for
10 min then resolved on RUNBLUE precast 12% SDS-PAGE
gels (Expedeon – San Diego, CA) and transferred to nitrocellulose
membranes. Blots were probed with mouse anti-FLAG primary
mAb (Sigma Aldrich – St. Louis, MO) and alkaline phosphatase
(AP)-conjugated goat anti-mouse IgG secondary Ab (Sigma-
Aldrich) and visualized using nitro-blue tetrazolium (NBT) and
5-bromo-4-chloro-39-indolyphosphate p-toluidine salt (BCIP) in
alkaline phosphatase buffer.
A-Pfs25 and A-Pfs28 were purified from 20 liters of TAP
medium grown in photobioreactors. Photobioreactors were
constructed from Nalgene carboys (part# – 2251-0050) fitted
with Nunc bulkhead adapters (part# – 6149-002) for bubbling air
through a 0.1 micron filter. Photobioreactors were inoculated with
250 ml starter cultures at late log phase and grown in the dark
until reaching an approximate density of 1610
6 cells/mL and then
shifted to high light (,5000 lux). Optimal yields were reached
when harvesting 5–8 hrs post-light induction. Cells were harvested
using a Lavin L2 continuous flow centrifuge (AML ind. – Hatboro,
PA) fed by a peristaltic pump. Total soluble protein was isolated as
described above. M2 anti-FLAG resin (Sigma Aldrich) was added
to the cleared lysate and rotated end over end at 4uC for 2 hrs.
Resin was washed with 20 volumes of lysis buffer twice and once
with lysis buffer without Tween 20. Resin was then collected by
filtration in a Bio-rad Econo-pac column and the protein was
Figure 5. Analysis of antibodies from mice immunized with
algae-produced Pfs25 or Pfs28. (A) ELISA titers of mouse anti-sera
elicited by algae-produced Pfs25 and Pfs28. Mice were immunized with
affinity purified a-Pfs25 or a-Pfs28 using complete Freund’s adjuvant
followed by boosters with incomplete Fruend’s adjuvant by intraper-
itoneal injection. Pooled sera was serially diluted and tested in triplicate
against the corresponding algae-produced Pfs antigen; error bars are
one standard deviation. Prebleed sera were tested as a negative control;
error bars are four standard deviations. (B–D) Western blot analysis of P.
falciparum mixed sexual stage lysates with anti-Pfs25-4B7 mAbs, a-Pfs
25 antisera, or a-Pfs28 antisera. Reduced and non-reduced sexual stage
lysates were resolved by SDS-PAGE and transferred to nitrocellulose.
Blots were probed with (B) anti-Pfs25-4B7 mAbs, (C) antibodies raised to
a- Pfs25, and (D) antibodies raised to a-Pfs28. (R – reduced, N – non-
reduced).
doi:10.1371/journal.pone.0037179.g005
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neutralized with Tris pH 8.0 to a final concentration of 50 mM.
Eluted fractions were resolved by SDS-PAGE and analyzed by
Western blot as described above. All fractions containing protein
were then combined and buffer exchanged using Vivaspin 6
centrifugal concentrators (GE Healthcare) with a 10 kDa molec-
ular weight cutoff into PBS. The concentration of purified protein
was determined using BioRad protein Assay (Biorad). Reduced
samples were prepared in SDS buffer with 10% b-mercapotoetha-
nol (BME) and heated to 90uC for 10 min. Non-reduced samples
were prepared using 4X Native Buffer (Expedeon). Both reduced
and non-reduced samples were resolved on 16% RUNBLUE
SDS-PAGE precast gels (Expedeon) for analysis by Western blot.
For gel staining, samples were resolved on 4–20% gradient SDS-
PAGE precast gels (Biorad) and stained using silver stain plus
(Biorad) or Coomassie-blue. Samples for Native-PAGE analysis
were prepared with 4X Native Buffer (Expedeon) and resolved by
10% Native-PAGE precast gel (Expedeon) then stained with
Coomassie-blue.
Anti-Pfs25 4B7 monoclonal antibody was prepared from mouse
hybridoma cell line 4B7.1.1 (ATCC – HB-12575). Cells were
grown in hybridoma-SFM media (Gibco, 12045) supplemented
with 10% FBS (Gemini) and antibodies were harvested after seven
days. Reduced and non-reduced a-Pfs25 and a-Pfs28 were
prepared as above. Both were resolved on RUNBLUE 16%
SDS-PAGE precast gels (Expedeon) and transferred to a
nitrocellulose membrane. The blot was probed using filtered
lysate containing anti-Pfs25 4B7 mAbs for a-Pfs25 or anti-Pfs28-
2D8. Antibody binding was detected using alkaline phosphatase-
conjugated goat anti-mouse secondary (Sigma-Aldrich) and
visualized using NBT and BCIP in alkaline phosphatase buffer.
Circular Dichroism
Far-UC CD spectra were recorded from 190–260 nm with a
0.1 nm data pitch using a Jasco J-815 spectropolarimeter and
1 mm path length. The cuvette chamber temperature was
maintained at 20uC by a Jasco PFD-425S/15 temperature unit.
Samples were at 21 mM and 27 mM in PBS for Pfs28 and Pfs25,
respectively. Spectra were acquired at 1 nm band width, 4 second
response time, and a scan speed of 100 nm/min. The results were
calculated after subtracting the PBS baseline spectra and reported
as mean residue ellipticity. Helical, b-strand, and turn content
were predicted using CDSSTR on Dichroweb [36,37].
Mass Spectrometry
Pfs25 treated with 0.5 mg/mL of iodoacetamide for 30 min at
37uC to carboxymethylate the cysteine residues that were not in
cysteine cross-link bonds. The reaction was quenched with
addition of 2 mM DDT followed by buffer exchange using
10 kDa cutoff membrane in 1X TNE buffer (50 mM Tris pH 8.0,
100 mM NaCl, 1 mM EDTA). RapiGest SF reagent (Waters
Figure 6. Indirect immunofluorescence using immune sera from mice immunized with algae-produced Pfs25 or Pfs28 on in-vitro
cultured P. falciparum gametocytes, gametes, and zygotes. DNA was stained using DAPI (blue) and antibody binding was visualized using
Alexa Fluor 488-conjugated rabbit anti-mouse IgG (green) for (A) a-Pfs25 antisera and (B) anti-Pfs25 4B7 mAbs. Scale bars, 1 mm.
doi:10.1371/journal.pone.0037179.g006
Figure 7. Standard membrane feeding assay with sera from
mice immunized with algae-produced Pfs25 or Pfs28. Mosquitos
midguts were dissected and analyzed for the presence of oocysts
following SMFA. Oocyst numbers are presented as a boxplot. The total
number of mosquitos analyzed is listed. Statistics were calculated with a
single-tailed Wilcoxon nonparametric comparison.
doi:10.1371/journal.pone.0037179.g007
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samples were boiled for 5 min. TCEP (Tris (2-carboxyethyl)
phosphine) was added to 1 mM (final concentration) and the
samples were incubated at 37uC for 30 min. Proteins samples
prepared as above were digested with trypsin (trypsin:protein ratio
– 1:50) overnight at 37uC. RapiGest was degraded and removed
by treating the samples with 250 mM HCl at 37uC for 1 h
followed by centrifugation at 14000 rpm for 30 min at 4uC. The
soluble fraction was then added to a new tube and the peptides
were extracted and desalted using Aspire RP30 desalting columns
(Thermo Scientific). Trypsin-digested peptides were analyzed by
high pressure liquid chromatography (HPLC) coupled with
tandem mass spectroscopy (LC-MS/MS) using nano-spray ioni-
zation. The nanospray ionization experiments were performed
using a TripleTOF 5600 hybrid mass spectrometer (ABSCIEX)
interfaced with nano-scale reversed-phase HPLC (Tempo) using a
10 cm-180 micron ID glass capillary packed with 5-mm C18
Zorbax
TM beads (Agilent Technologies, Santa Clara, CA).
Peptides were eluted from the C18 column into the mass
spectrometer using a linear gradient (5–60%) of ACN (Acetoni-
trile) at a flow rate of 250 mL/min for 1 h. The buffers used to
create the ACN gradient were: Buffer A (98% H2O, 2% ACN,
0.2% formic acid, and 0.005% TFA) and Buffer B (100% ACN,
0.2% formic acid, and 0.005% TFA). MS/MS data were acquired
in a data-dependent manner in which the MS1 data was acquired
at m/z of 400 to 1250 Da and the MS/MS data was acquired
from m/z of 50 to 2,000 Da. Finally, the collected data were
analyzed using MASCOTH (Matrix Sciences) and Protein Pilot 4.0
(ABSCIEX) for peptide identifications.
Preparation of mouse antisera
Animal experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of the University of
California. Balb/c mice were vaccinated by intraperitoneal
injection with 25 mg of affinity purified a-Pfs25 or a-Pfs28
emulsified in complete Freund’s adjuvant (Sigma-Aldrich). Four
boosters were given at two week intervals with 15 mg of affinity
purified a-Pfs25 or a-Pfs28 using incomplete Fruend’s adjuvant
(Sigma-Aldrich). Blood was collected prior to immunization and
one week following the final immunization.
Enzyme-linked immunosorbent assay
The percent of a-Pfs25 and a-Pfs28 of the soluble protein
fraction was measured by ELISA. The soluble protein lysates from
JAG9 (a-Pfs25) and JAG15 (a-Pfs28) were compared to soluble
protein from the untransformed parental strain (W1.1) with a
known amount of affinity purified a-Pfs25 or a-Pfs28 as follows.
Soluble protein fractions were prepared by sonication followed by
centrifugation at 20,0006 g. Affinity purified a-Pfs25 or a-Pfs28
was mixed with soluble protein from W1.1 at a 1:50 ratio, or 2%
recombinant protein, and diluted to a final concentration of
0.5 mg/mL in PBS. A standard curve was then prepared using
two-fold serial dilutions with a 0.5 mg/ml solution of W1.1 soluble
protein. MaxiSorpTM plates (Nunc – Rochester, NY) were coated
in triplicate with 50 mg of soluble protein from JAG9, JAG15, or
the prepared standard curve and incubated overnight at 4uCo na
rocker. Wells were washed three times with PBS with 0.1% Tween
(PBS-T) and blocked with 5% milk in PBS-T for 2 hrs at room
temperature. A-Pfs25 and a-Pfs28 were detected with M2 anti-
FLAG mAbs diluted 1:4000 in PBS-T and goat anti-mouse horse
radish peroxidase (Thermo Scientific – Rockford, IL) at 1:5000.
Antibody binding was detected using the TMB substrate kit
(Thermo Scientific) and read with an Infinite M200 pro plate
reader (Tecan – Switzerland) at 450 nm. Readings from JAG9 and
JAG15 soluble protein were compared to the standard curves
prepared with purified protein.
IgG titers in the mouse antisera against a-Pfs25 and a-Pfs28
were measured by ELISA as follows. A-Pfs25 and a-Pfs28 were
diluted to 1 mg/ml in PBS and used to coat 96-well MaxiSorp
TM
plates (Nunc – Rochester, NY) and incubated overnight at 4uCo n
a rocker. Wells were washed three times with PBS-T and blocked
with 5% milk in PBS-T for 2 hours at room temperature. Serum
samples were prepared by 1:5 serial dilutions from 1:100 to
1:62500, followed by 1:2 dilutions from 1:65000 to 8610
7, plated
in triplicate, and incubated overnight at 4uC. IgG titers were
detected using AP-conjugated goat anti-mouse IgG (Sigma-
Aldrich) at 1:4000 in PBS-T for two hours at room temperature
and visualized using p-Nitrophenylphosphate (Enzo Life Sciences
– Farmingdale, NY) as the substrate. Absorbances were measured
at 450 nm using Infinite M200 pro plate reader (Tecan –
Switzerland).
Western Blotting of parasite lysates
Plasmodium falciparum strain NF54 was maintained in vitro in
continuous cultivation. Gametocytes, macrogametes, zygotes, and
ookinetes were cultured and purified as previously described [45].
For antibodies raised to a-Pfs25, 2 mg of reduced and nonreduced
parasite lysate was prepared as described above and resolved on
RUNBLUE 12% SDS-PAGE precast gels (Expedeon). Resolved
proteins were transferred to nitrocellulose and probed with
antisera raised to a-Pfs25 at a 1:100 dilution. Identical blots were
prepared and probed with anti-Pfs25 4B7 mAbs or preimmune
sera. For antibodies raised to a-Pfs28, 20 mg was prepared in an
identical manner and probed with a-Pfs28 antisera at a 1:100
dilution or preimmune sera. All membranes were visualized using
AP-conjugated goat anti-mouse IgG antibodies.
Indirect Immunofluorescence
Fixed, permeabilized gametocytes, macrogametes, and zygotes
were subjected to IFA. Parasites were heat-fixed onto 10-well glass
slides (Fisher Scientific). Fixed cells were permeabilized by
incubation in PBS containing 3% bovine serum albumin and
0.1% Triton X-100 at room temperature for 15 minutes followed
by blocking for 2 hrs at room temperature in 3% BSA in PBS-T.
The preparations were incubated with a-Pfs25 or a-Pfs28 antisera
(1:100 dilution) or 4b7 mAbs overnight at 4uC followed by Alexa
Fluor 488 goat anti-mouse IgG (1:500 dilution; Molecular Probes)
at room temperature for 1 hr. Parasite nuclei were stained with
2 mg/mL 49-6-Diamidino-2-phenylindole (DAPI; Molecular
Probes) at room temperature for 5 min. Slides were mounted
with SlowFadeH anti-fade kit (Molecular Probes)and images were
acquired using an Applied Precision Spectris microscope and
deconvolved using Softworx software (Applied Precision –
Issaquah, Washington). Images were adjusted for contrast in
Softworx and exported as tiffs and assembled with Adobe
Photoshop.
Standard Membrane Feeding Assay
Transmission blocking activity was assessed by standard
membrane feeding [46]. Anopheles stephensi STE2 was maintained
at 27uC and 80% relative humidity on a 12 hr day/night light
cycle. Larvae were fed a diet of powdered fish food (Tetramin)
mixed with yeast. Adults were provided a 10% sugar solution.
Four to six day-old female A. stephensi mosquitoes were fed with P.
falciparum NF 54 gametocytes in the presence of heat inactivated
control or immune sera or mAbs using a membrane feeding
apparatus. Heat inactivation was performed at 56uC for 45 min.
After 15 min of feeding, un-engorged mosquitoes were removed
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standard conditions [47]. Midguts were dissected 9 days after the
infectious bloodmeal, stained with 0.1% mercurochrome and the
number of oocysts in each preparation counted. Uninfected
bloodmeals were provided to wild-type control mosquitoes
following the membrane feeding. Infected female mosquitoes were
dissected for oocyst counts nine days after infection. Statistics were
calculated in JMP ver. 9.0.2 (SAS – Cary, NC) using a single tailed
Wilcoxon nonparametric comparison.
Supporting Information
Figure S1 Silver stain analysis of algae-produced Pfs25
and Pfs28. Increasing amounts of affinity purified a-Pfs25 and a-
Pfs28 (100, 200, and 400 ng) and 200 ng of BSA were resolved on
16% SDS-PAGE and total protein was detected using silver stain.
(TIF)
Figure S2 Indirect immunofluorescence using immune
sera from mice injected with algae-produced Pfs25 or
Pfs28 on in-vitro cultured P. falciparum gametocytes,
gametes, and zygotes. DNA was stained using DAPI (blue) and
antibody binding was visualized using Alexa Fluor 488-conjugated
rabbit anti-mouse IgG (green) for a-Pfs25 antisera, a-Pfs28
antisera, anti-Pfs25 4B7 mAbs, and sera from isogenic unvacci-
nated mice.
(TIF)
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